Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

NCT02640209 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
TERMINATED
Status
20
Enrollment
OTHER
Sponsor class

Stopped Study is terminated due to administrative reasons.

Conditions

Interventions

Sponsor

University of Pennsylvania